SPARQL | HTML5 RDFa and Microdata document 
  https://identifiers.org/wikipathways/WP408   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/a5a17   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/ed7be   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id1552b68   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id214731c2   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id4ce306be   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id570aed5e   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id7e19e441   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id89311299   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id977e17f7   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/id9a960468   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/ida6ac42e8   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/idb5f28f5a   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/idbc9182bd   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/idcc588a5e   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/idd3210da8   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/idd87eb1e   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/idef7bab3c   http://rdf.wikipathways.org/Pathway/WP5035_r134596/WP/Interaction/idf1a7869a   https://identifiers.org/wikipathways/WP5035_r134596   
      http://www.w3.org/1999/02/22-rdf-syntax-ns#type   
          http://www.w3.org/2004/02/skos/core#Collection 
          http://vocabularies.wikipathways.org/wp#Pathway 
         http://vocabularies.wikipathways.org/wp#cellTypeOntologyTag   
          http://purl.obolibrary.org/obo/CL_0000057 
         http://vocabularies.wikipathways.org/wp#diseaseOntologyTag   
          http://purl.obolibrary.org/obo/DOID_0080600 
          http://purl.obolibrary.org/obo/DOID_3770 
         http://vocabularies.wikipathways.org/wp#isAbout   
          http://rdf.wikipathways.org/Pathway/WP5035_r134596 
         http://vocabularies.wikipathways.org/wp#ontologyTag   
          http://purl.obolibrary.org/obo/DOID_3770 
          http://vocabularies.wikipathways.org/wp#Curation:AnalysisCollection 
          http://purl.obolibrary.org/obo/DOID_0080600 
          http://vocabularies.wikipathways.org/wp#Curation:ONTOX 
          http://purl.obolibrary.org/obo/CL_0000057 
          http://purl.obolibrary.org/obo/PW_0000527 
          http://vocabularies.wikipathways.org/wp#Curation:AOP 
          http://vocabularies.wikipathways.org/wp#Curation:COVID19 
          http://purl.obolibrary.org/obo/PW_0000526 
         http://vocabularies.wikipathways.org/wp#organism   
          http://purl.obolibrary.org/obo/NCBITaxon_9606 
         http://vocabularies.wikipathways.org/wp#organismName   http://vocabularies.wikipathways.org/wp#pathwayOntologyTag   
          http://purl.obolibrary.org/obo/PW_0000527 
          http://purl.obolibrary.org/obo/PW_0000526 
         http://xmlns.com/foaf/0.1/img   
          https://www.wikipathways.org//wpi/wpi.php?action=downloadFile&type=png&pwTitle=Pathway:WP5035&oldid=134596 
          https://www.wikipathways.org//wpi/wpi.php?action=downloadFile&type=svg&pwTitle=Pathway:WP5035&oldid=134596 
         http://xmlns.com/foaf/0.1/page   
          http://www.wikipathways.org/instance/WP5035_r134596 
         http://purl.org/dc/elements/1.1/identifier   
          https://identifiers.org/wikipathways/WP5035 
         http://purl.org/dc/elements/1.1/source   http://purl.org/dc/elements/1.1/title   
          ACE2 inhibition leads to pulmonary fibrosis 
         http://purl.org/dc/terms/description   
          This AOP outlines how ACE-2 plays a detrimental role in causing fibrotic damage to the lung by influencing various factors such as fibrogenic components, proinflammatory cytokines, and a lack of oxygen. When the activity of ACE2 is suppressed, the conversion of Ang II into Ang-(1-7) is not properly facilitated. Consequently, the levels of proinflammatory Ang II rise, while the levels of anti-inflammatory Ang-(1-7) decrease. Notably, ACE2 inhibition has been observed to raise the levels of Ang II peptides, which are a ligand for the type 1 angiotensin receptor (AT1R). This phenomenon is considered a significant risk factor for lung fibrosis, vasoconstriction, endothelial dysfunction, and cell death. 
         http://purl.org/dc/terms/identifier   http://purl.org/dc/terms/references   
          https://identifiers.org/pubmed/33677612 
          https://identifiers.org/pubmed/34095051 
          https://identifiers.org/pubmed/35032963 
         http://purl.org/spar/cito/cites   
          https://identifiers.org/pubmed/33677612 
          https://identifiers.org/pubmed/34095051 
          https://identifiers.org/pubmed/35032963 
            https://identifiers.org/aop.events/1115   https://identifiers.org/aop.events/1172   https://identifiers.org/aop.events/1276   https://identifiers.org/aop.events/1740   https://identifiers.org/aop.events/1743   https://identifiers.org/aop.events/1752   https://identifiers.org/aop.events/1851   https://identifiers.org/aop.events/68   https://identifiers.org/pubmed/33677612   https://identifiers.org/pubmed/34095051   https://identifiers.org/pubmed/35032963   https://identifiers.org/wikipathways/WP2725   https://identifiers.org/wikipathways/WP2729   https://identifiers.org/wikipathways/WP4562   https://identifiers.org/wikipathways/WP4756   https://identifiers.org/wikipathways/WP5035   https://identifiers.org/wikipathways/WP5036   https://identifiers.org/wikipathways/WP5068   https://identifiers.org/wikipathways/WP5088   https://identifiers.org/wikipathways/WP5089   https://identifiers.org/wikipathways/WP5095   https://identifiers.org/wikipathways/WP554